Gsk Share Discussion Threads

[rikky72] 11/1/2024 09:34

I think it was calculated so that the HLN share capital issue was worth 20% of the value of the old combined GSK.But I would be very happy to exit somewhere between 18 and 19 quid

[mhrangoon] 11/1/2024 06:40

I dont think this formula is correct as total number of share allocation reduced.

[laurence llewelyn binliner] 10/1/2024 18:17

The pre split share price in summer 2022 was about 1800, and with the share price today at 1570, plus the HLN share price of 337 gives us c1900 total, so we are ahead again at last 18 months later..

GSK at 1800 stand alone would be great to see with HLN alongside adding value for those holders who kept them, as soon as they hit their debt to EBITDA ratio the dividend will pick up pace there too..

[dplewis1] 10/1/2024 11:11

DB raises target price to 1850p from 1750p

[mj19] 10/1/2024 08:04

GSK, a pharmaceutical group, said Nucala (mepolizumab) has been approved in China for use in severe asthma with an eosinophilic phenotype.

[dplewis1] 09/1/2024 16:15

GSK exec says well on track to hit all targets company set out for 2026 - JPM healthcare conference

[blackhorse23] 09/1/2024 12:07

Money moved to APH , great dividend yields & excellent healthcare company

[tuftymatt] 09/1/2024 09:09

Big pharma just gets that bit bigger.

Good luck all 👍🏻

[tradermichael] 09/1/2024 08:06

GSK said it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.

The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.

The portfolio addition "could expand the reach of our current respiratory biologics portfolio, to the 40% of severe asthma patients with low type 2 inflammation where treatment options are still needed," Chief Scientific Officer Tony Wood said.

The additional payment of up to $400 million is dependent on certain regulatory milestones being met, it said.

[tradermichael] 06/1/2024 11:24

12/2023 Q3 Dividend:
Pays next Thursday 11-Jan-24 (14p/share)

[tuftymatt] 04/1/2024 09:55

I hope you are right but personally I think that may be a bit of a stretch.

This year though I wouldn't bet against.

Good luck all 👍🏻

[alibizzle] 04/1/2024 09:35

Hopefully this momentum can be maintained, and reach £17 by end of month

[tradermichael] 03/1/2024 12:03

I think that Jefferies loves GSK nearly as much as I do ..... ;0)

[patientcapital] 03/1/2024 10:55

GSK: Stock price offers attractive risk remuneration, according to Jefferies -- Market TalkSource: MF Dow Jones (English)Original article published in Dow Jones English Newswire, translated by Il Sole 24 Ore Radiocor editorial staff.(Il Sole 24 Ore Radiocor Plus) - Milan, 3 Jan - ? GSK is expected to give at least one-digit EPS growth guidance for 2024 and resolve the Zantac litigation case within the next few months, Jefferies analysts write in a note raising the rating on the buy-to-hold stock.Analysts estimate the pharmaceutical company will pay between $3 billion and $4 billion to resolve the case.The company's growth profile is undervalued and the current share price offers an attractive risk remuneration.Jefferies raised the stock's target price to 1,900 pence from 1,550 pence. Stocks are currently up 2.2% and 4.3% in the last 12 months. ([e-mail].)(END) Dow Jones NewswiresJanuary 03, 2024 03:50 ET (08:50 GMT)Copyright (c) 2024 Dow Jones-Radiocor

[pj84] 03/1/2024 10:19

The following is an extract from the article: -

GSK’s revival ‘will become clear to investors in 2024’

...


“When we meet investors, the things that they say to us are, ‘We want to see visible progress in the pipeline.’ So that’s readouts and we’ve got a number of those coming up next year in oncology and respiratory, as well as infectious diseases.”

They include hopes for Blenrep, a blood cancer treatment, which produced encouraging trial results in November, a year after it had suffered a clinical setback. “If we can show that there’s a pathway back to the market, this is an important element for our credibility,” Miels said

Another is depemokimab, a twice-yearly injection to treat asthma and other respiratory diseases, and camlipixant, a potential treatment for refractory chronic cough, taken as a twice-daily pill. Both are potential blockbusters, or drugs that generate annual sales of at least $1 billion for their company, in late-stage development.

GSK has been bolstering its late-stage pipeline through bolt-on and licensing deals, including agreements in October and December for cancer drugs developed by Hansoh Pharma, of China.

...

[patientcapital] 03/1/2024 10:10

Walmsley is in the DM today as well.

[zho] 03/1/2024 09:58

Try using or

[tradermichael] 03/1/2024 09:56

Anyone know what the TIMES said about GSK, please?

[montyhedge] 03/1/2024 09:18

My choice for 2024, GSK, Bats, Phoenix for nice dividends and one growth share Fortinet Inc on Nasdaq.GLA for 2024.

[mj19] 03/1/2024 09:03

Still cheap this year should take us to £20

[dplewis1] 03/1/2024 08:51

GSK is expected to guide for at least low single digit EPS growth for 2024 and settle the Zantac litigation case within the coming months, Jefferies analysts write in a research note as they raise their rating on the stock to buy from hold. They estimate that the pharma company will pay between $3bn and $4bn to settle the case. The company's growth profile is under appreciated and the current share price offers attractive risk reward.

[tuftymatt] 03/1/2024 08:41

Wow that's some increase by Jefferies!!

I trade these and had a sell order in at 1498 before seeing the Times headline. Closed that and am hoping for a fair bit more now.

Good luck all 👍🏻

[mj19] 03/1/2024 08:13

GSK : JEFFERIES RAISES TARGET PRICE TO 1,900P FROM 1,550PThis news story contains no content

[supermarky] 03/1/2024 08:06

Nice to see this revving up for the start of the year